Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Expected to Rise, Piper Sandler Analyst Says

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective hoisted by stock analysts at Piper Sandler from $44.00 to $56.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler‘s price objective suggests a potential upside of 29.72% from the stock’s previous close.

A number of other analysts also recently weighed in on TEVA. Leerink Partners raised their price target on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. HC Wainwright began coverage on shares of Teva Pharmaceutical Industries in a report on Monday, November 2nd. They issued a “buy” rating and a $52.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Oppenheimer raised their price objective on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. Finally, Weiss Ratings raised shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.15.

Teva Pharmaceutical Industries Trading Up 1.8%

Shares of TEVA opened at $43.17 on Thursday. Teva Pharmaceutical Industries has a one year low of $24.01 and a one year high of $43.34. The stock has a 50-day moving average price of $39.88 and a 200 day moving average price of $34.96. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95. The company has a market capitalization of $50.30 billion, a P/E ratio of 18.76, a P/E/G ratio of 3.97 and a beta of 0.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. During the same period in the previous year, the business earned $0.78 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was down 1.9% compared to the same quarter last year. Sell-side analysts forecast that Teva Pharmaceutical Industries will post 1.98 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Mark Sabag sold 46,000 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the completion of the transaction, the insider owned 80,760 shares in the company, valued at $3,386,266.80. The trade was a 36.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Brian Savage sold 7,342 shares of the company’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the transaction, the insider owned 8,500 shares of the company’s stock, valued at approximately $330,225. The trade was a 46.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 420,942 shares of company stock valued at $16,572,473. Insiders own 0.54% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently added to or reduced their stakes in TEVA. WCM Investment Management LLC grew its position in shares of Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after acquiring an additional 26,813,522 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 1.3% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 39,422,212 shares of the company’s stock worth $1,561,120,000 after acquiring an additional 500,000 shares during the period. Wellington Management Group LLP lifted its position in Teva Pharmaceutical Industries by 5.8% in the 2nd quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock valued at $259,899,000 after purchasing an additional 419,329 shares during the last quarter. Janus Henderson Group PLC lifted its position in Teva Pharmaceutical Industries by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock valued at $145,076,000 after purchasing an additional 72,880 shares during the last quarter. Finally, Bessemer Group Inc. lifted its position in Teva Pharmaceutical Industries by 1.6% in the 1st quarter. Bessemer Group Inc. now owns 4,350,483 shares of the company’s stock valued at $131,036,000 after purchasing an additional 70,058 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Top Teva Pharmaceutical Industries Stories

Investors following TEVA have been watching these stories:

• Positive Sentiment: R&D updates highlighted prospective first-in-class treatments for Tourette syndrome, celiac disease and scarring associated with inflammatory bowel disease. These programs could strengthen Teva’s future pipeline, although development and commercial outcomes remain uncertain. Teva pipeline report
• Neutral Sentiment: HC Wainwright maintained a Buy rating and $52 price target, raising its FY2027 EPS estimate to $3.07 from $3.03. However, it also cut some quarterly estimates, including Q4 2026 EPS to $0.64 from $0.75, making the revisions mixed overall. HC Wainwright estimates
• Negative Sentiment: Healthcare shares traded lower Wednesday afternoon, a sector-wide headwind that could weigh on TEVA independently of company-specific developments. Healthcare sector update

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.